Johns Hopkins Launches New Institute for Cancer Immunotherapy

To Johns Hopkins Health System employees

Dear Colleagues:

Today we are announcing a $125 million philanthropic investment that will establish the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy. The Institute will focus on the development of promising therapies that unleash the power of patients' natural defense—their immune system—to seek out and eradicate cancer. The center will foster cross-disciplinary collaboration among researchers and unite our world-class Kimmel Cancer Center immunology, genetics, microbiology, and biomedical engineering programs.

The new center is made possible by the visionary leadership of Michael R. Bloomberg, philanthropist, entrepreneur, and three-term mayor of New York City, and Jones Apparel Group founder Sidney Kimmel, who each contributed $50 million. More than a dozen additional supporters provided a total of $25 million. Together, these investments will allow our researchers to collaborate in new ways, to more rapidly pursue innovative ideas, and to turn novel advances into patient treatments.

In making this transformative commitment, our donors stand with our impressive team at the Kimmel Cancer Center to honor the creativity, humanity, and collaborative spirit that make our researchers and clinicians of the Bloomberg~Kimmel Institute for Cancer Immunotherapy stand apart. We are profoundly grateful.

We are pleased to welcome Vice President Biden, our donors, and friends to the East Baltimore campus to launch the institute at 12:30 p.m. today. You are invited to watch the event via livestream. We hope you share our pride and excitement as our institution dedicates itself anew to this work and takes a historic step toward the promise of beating 100 percent of cancers.

Sincerely,

Ronald J. Daniels
President
CEO, Johns Hopkins Medicine

Paul B. Rothman, M.D.
Dean of the Medical Faculty
CEO, Johns Hopkins Medicine